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Background
Development of novel (immune) therapies is of utmost
importance to improve survival in relapsed pediatric-AML
(acute myeloid leukemia). We aim to develop a powerful
and safe therapy consisting of 2 synergistic components:
Cord Blood (CB) HSCT and vaccination with CB-derived
Wilms Tumor-1 (WT1) mRNA-electroporated dendritic
cells (DCs).
Materials & methods
After isolation, the CD34+ CB stem cells were cultured
using a two-step protocol. First, they were expanded using
a combination of (growth) factors (Flt3L, SCF, IL-3 and
IL-6). Next, the cells were differentiated towards DCs for
one week using medium containing Flt3L, SCF, GM-CSF,
IL-4 and human serum followed by a CYTOMIX (IL-1b,
IL-6, TNF-a and PGE2)-induced maturation for the last
24 hours. Finally, the CB-DC culture was electroporated
with WT1-mRNA and their phenotype (cell surface
markers) and function (migration and antigen presenta-
tion) were assessed.
Results
Using the two-step protocol a total cell expansion of
300-500 fold was achieved. Based on surface marker
expression, at least 5 different DC subsets could be distin-
guished in our CB-DC cultures. Since no differences in
antigen presentation capacity between the DC subsets
were detected, the whole CB-DC culture was used in all
phenotypic and functional assays. The maturation using
CYTOMIX induced upregulation of costimulatory
molecules and CCR7. These cells were also functional,
showing enhanced CCR7-dependent migration towards
CCL21 in a trans-well migration assay. Finally, the stimu-
lation of WT1-specific T cells by the CB-DCs, matured
using CYTOMIX and electroporated with WT1 mRNA,
confirmed presentation of WT1 antigens.
Conclusion
We have developed and tested an in vitro system for cul-
turing large amounts of DCs from the CD34+ CB stem
cells. Both the phenotypic and functional data support the
use of the whole CB-DC culture as vaccine. The next step
will be to translate the preclinical protocol to GMP
production of a clinical grade vaccine.
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